Completed PHASE2 INTERVENTIONAL 7-arm NCT01044758

Levetiracetam and Memory Function in Amnestic Mild Cognitive Impairment (MCI)

Bridging Cognitive Aging in Rodents to Man Using fMRI in Amnestic MCI

Sponsor: Johns Hopkins University

Conditions Mild Cognitive Impairment (MCI)

Interventions Levetiracetam 125mg Levetiracetam 250mg Levetiracetam 62.5mg Placebo

Updated 9 times since 2017 Last updated: Jul 19, 2017 Started: Dec 31, 2009 Primary completion: Jul 31, 2012 Completion: Jul 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01044758, this PHASE2 trial focuses on Mild Cognitive Impairment (MCI) and remains completed. Sponsored by Johns Hopkins University, it has been updated 9 times since 2009, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2023 — Jul 2024 [monthly]

Completed PHASE2
Dec 2022 — Jan 2023 [monthly]

Completed PHASE2
Jan 2021 — Dec 2022 [monthly]

Completed PHASE2

▶ Show 4 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Sep 2017 — Jun 2018 [monthly]

Completed PHASE2
Feb 2017 — Sep 2017 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Dec 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Johns Hopkins University
National Institute on Aging (NIA)

Data source: Johns Hopkins University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Baltimore, United States